Johnson & Johnson Q1 2019 earnings drop 14%

Johnson & Johnson’s mounting legal costs ate into its first-quarter profits, which dropped 14% as of which fights thousands of lawsuits over its talc baby powder as well as shelled out almost $400 million to settle 25,000 cases over its blockbuster blood thinner Xarelto.

Still, the health company on Tuesday reported better-than-expected earnings, as well as its shares closed up more than 1%. J&J reported first-quarter net income of $3.75 billion, or $1.39 per share, down 14% by $4.37 billion, or $1.60 per share a year earlier. When adjusted, J&J earned $2.10 per share, above the $2.03 per share expected by analysts surveyed by Refinitiv.

“The strength of our first quarter results reinforce the confidence we have in our broad-based business,” Chief Financial Officer Joseph Wolk said Tuesday on a call with analysts. “We continue to manage our portfolio with discipline as well as make investments across the enterprise of which position as well to achieve long-term sustainable growth across three vital aspects of health care.”

J&J’s legal expenses have mushroomed in recent months. The company spent $423 million on litigation expenses during the first quarter, on top of $1.29 billion during the fourth quarter. Its legal costs during the first quarter of 2018 rounded to zero.

The company is usually defending itself in thousands of lawsuits accusing the company’s talc baby powder of causing cancer. However, a bulk of its legal costs during the first quarter came by J&J’s settlement of more than 25,000 lawsuits over the blockbuster blood thinner Xarelto, spokesman Ernie Knewitz said. The $775 million settlement was split with its European partner on the drug, Bayer, leaving J&J which has a $387.5 million bill, he said in an email.

“While there have been several trials where juries have awarded significant verdicts against Johnson & Johnson [inside the talc cases], each one of which has been heard on appeal have been overturned,” Knewitz said. The talc litigation accounted for just 10% of the company’s $1.29 billion in legal costs during the fourth quarter, he said.

Sales barely budged, rising to $20.02 billion by $20.01 billion during the first three months last year. Analysts expected a decline to $19.61 billion.

More than half its revenue came by prescription drug sales, which rose to $10.24 billion by $9.84 billion inside the year-earlier quarter. Analysts were expecting revenue of $9.83 billion, according to estimates compiled by StreetAccount.

The company narrowed its full-year earnings forecast to a range of $8.53 to $8.63 per share by its previous estimate of between $8.50 as well as $8.65. of which didn’t change its projected sales of $80.4 billion to $81.2 billion for 2019.

Prescription drug sales helped boost earnings, despite brand-new generic drug competition against its Zytiga prostate cancer drug.

Zytiga lost its patent protection last year, as well as its sales during the first three months of the year fell 19.6% to $679 million by $845 million the year earlier. Anti-inflammatory drug Remicade sales also fell to $1.1 billion by $1.39 billion by last year.

Two drugs stood out in boosting J&J’s results with better-than-expected sales. Anti-inflammatory treatment Stelara revenue increased to $1.41 billion by $1.06 billion, surpassing estimates of $1.36 billion. Multiple myeloma drug Darzalex increased to $629 million by $432 inside the same time last year. Analysts had expected $627.7 million.

Consumer sales, which includes Aveeno lotions as well as over-the-counter drugs like Tylenol, dipped to $3.32 billion by $3.4 billion last year. They fell short of StreetAccount estimates of $3.41 billion. Medical device sales decreased to $6.46 billion by $6.77 billion inside the year-earlier quarter, though they came in better than the $6.34 billion analysts had expected.

A Reuters report in December claimed J&J knew for decades its talc baby powder contained asbestos, tanking the company’s usually stable stock. J&J has repeatedly denied any wrongdoing as well as stands behind its namesake baby powder.

The concerns threaten J&J’s namesake baby care brand, which J&J relaunched last spring. inside the first quarter, baby care revenue fell to $394 million by $457 million last year.

J&J’s Spravato, a ketamine-like drug for treatment-resistant depression, won Food as well as Drug Administration approval in March. Since then, up to 800 treatment centers have been certified to administer the drug as well as the first patients have been dosed, Jennifer Taubert, executive vice president of pharmaceuticals told analysts.